BioMarin paints picture of dwarfism drug’s wider efficacy on Phase III win

BioMarin has filed an NDA with US regulators for Voxzogo in hypochondroplasia following these positive results. The company has filed an NDA with US regulators for Voxzogo in hypochondroplasia following these positive results. BioMarin has filed for Voxzogo’s US approval in hypochondroplasia, a form of dwarfism. Credit: Tada Images / Shutterstock.com. BioMarin has debuted new data from a Phase III trial on its dwarfism drug, Voxzogo (vosoritide), which the company hopes will form the basis for the drug’s US approval in a subset of the genetic condition. As per updated results from the late-stage CANOPY-HCH-3 study (NCT06455059), which were presented…

Source: Clinical Trials Arena